ArticleNeuropsychiatric disease and treatment2008
Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.
Article in Neuropsychiatric disease and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A review of the methods used to estimate the cost of Alzheimer's disease in the United States.American journal of Alzheimer's disease and other dementias · 2011Pooled it
- Neurophysiological Hallmarks of Neurodegenerative Cognitive Decline: The Study of Brain Connectivity as A Biomarker of Early Dementia.Journal of personalized medicine · 2020Review
- Use of medications of questionable benefit in advanced dementia.JAMA internal medicine · 2014Article
- Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing.BMC neurology · 2014Article
- Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.Journal of the American Geriatrics Society · 2011Article
- Update on the use of memantine in Alzheimer's disease.Neuropsychiatric disease and treatment · 2009Article
- Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease.Neuropsychiatric disease and treatment · 2009Article
- Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is an important and rapidly expanding public health problem. Its large economic burden is a result of its disabling nature, chronicity, and high prevalence in older segments of the population. Current treatments of AD have been criticized for providing insufficient benefit to justify their costs, but variability in assessing both costs and benefits make evaluation of the existing data problematic. Inclusion of the value of caregiver time is a major driver of the determination of cost-effectiveness. Population-based studies and those based on application of economic models to other study outcomes tend to identify greater cost-effectiveness than prospectively collected data. Differences in healthcare economics across countries also limit generalization of specific study findings. The current state of evidence suggests that treatment decisions in AD should be based on assessment of benefit in individual patients rather than broader societal economic factors.
Indexed as
Identifiers
18830441PMC2526383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.